Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 71

1.

Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer.

Balaban S, Nassar ZD, Zhang AY, Hosseini-Beheshti E, Centenera MM, Schreuder M, Lin HM, Aishah A, Varney B, Liu-Fu F, Lee LS, Nagarajan SR, Shearer RF, Hardie RA, Raftopulos NL, Kakani MS, Saunders DN, Holst J, Horvath LG, Butler LM, Hoy AJ.

Mol Cancer Res. 2019 Jan 15. doi: 10.1158/1541-7786.MCR-18-0347. [Epub ahead of print]

PMID:
30647103
2.

Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.

Mahon KL, Qu W, Lin HM, Spielman C, Cain D, Jacobs C, Stockler MR, Higano CS, de Bono JS, Chi KN, Clark SJ, Horvath LG.

Eur Urol. 2018 Nov 19. pii: S0302-2838(18)30855-8. doi: 10.1016/j.eururo.2018.11.001. [Epub ahead of print]

PMID:
30466891
3.

An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy.

Zhang AY, Chiam K, Haupt Y, Fox S, Birch S, Tilley W, Butler LM, Knudsen K, Comstock C, Rasiah K, Grogan J, Mahon KL, Bianco-Miotto T, Ricciardelli C, Böhm M, Henshall S, Delprado W, Stricker P, Horvath LG, Kench JG.

Int J Cancer. 2019 Mar 1;144(5):1151-1159. doi: 10.1002/ijc.31906. Epub 2018 Dec 4.

PMID:
30288742
4.

A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosis.

Vafaee F, Diakos C, Kirschner MB, Reid G, Michael MZ, Horvath LG, Alinejad-Rokny H, Cheng ZJ, Kuncic Z, Clarke S.

NPJ Syst Biol Appl. 2018 Jun 1;4:20. doi: 10.1038/s41540-018-0056-1. eCollection 2018.

5.

Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten.

Nair SS, Luu PL, Qu W, Maddugoda M, Huschtscha L, Reddel R, Chenevix-Trench G, Toso M, Kench JG, Horvath LG, Hayes VM, Stricker PD, Hughes TP, White DL, Rasko JEJ, Wong JJ, Clark SJ.

Epigenetics Chromatin. 2018 May 28;11(1):24. doi: 10.1186/s13072-018-0194-0.

6.

MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer.

Lin HM, Nikolic I, Yang J, Castillo L, Deng N, Chan CL, Yeung NK, Dodson E, Elsworth B, Spielman C, Lee BY, Boyer Z, Simpson KJ, Daly RJ, Horvath LG, Swarbrick A.

Sci Rep. 2018 May 18;8(1):7820. doi: 10.1038/s41598-018-26050-y.

7.

A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers.

Roohullah A, Cooper A, Lomax AJ, Aung J, Barge A, Chow L, McHale M, Desai J, Whittle JR, Tran B, de Souza P, Horvath LG.

Invest New Drugs. 2018 May 16. doi: 10.1007/s10637-018-0588-7. [Epub ahead of print]

PMID:
29766337
8.

Enduring epigenetic landmarks define the cancer microenvironment.

Pidsley R, Lawrence MG, Zotenko E, Niranjan B, Statham A, Song J, Chabanon RM, Qu W, Wang H, Richards M, Nair SS, Armstrong NJ, Nim HT, Papargiris M, Balanathan P, French H, Peters T, Norden S, Ryan A, Pedersen J, Kench J, Daly RJ, Horvath LG, Stricker P, Frydenberg M, Taylor RA, Stirzaker C, Risbridger GP, Clark SJ.

Genome Res. 2018 May;28(5):625-638. doi: 10.1101/gr.229070.117. Epub 2018 Apr 12.

9.

Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants.

Nguyen EV, Centenera MM, Moldovan M, Das R, Irani S, Vincent AD, Chan H, Horvath LG, Lynn DJ, Daly RJ, Butler LM.

Mol Cell Proteomics. 2018 Aug;17(8):1470-1486. doi: 10.1074/mcp.RA118.000633. Epub 2018 Apr 9.

PMID:
29632047
10.

Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.

Lin HM, Lee BY, Castillo L, Spielman C, Grogan J, Yeung NK, Kench JG, Stricker PD, Haynes AM, Centenera MM, Butler LM, Shreeve SM, Horvath LG, Daly RJ.

Prostate. 2018 Mar;78(4):308-317. doi: 10.1002/pros.23476. Epub 2018 Jan 5.

PMID:
29314097
11.

Discovering cancer vulnerabilities using high-throughput micro-RNA screening.

Nikolic I, Elsworth B, Dodson E, Wu SZ, Gould CM, Mestdagh P, Marshall GM, Horvath LG, Simpson KJ, Swarbrick A.

Nucleic Acids Res. 2017 Dec 15;45(22):12657-12670. doi: 10.1093/nar/gkx1072.

12.

Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer.

Kalsbeek AMF, Chan EKF, Grogan J, Petersen DC, Jaratlerdsiri W, Gupta R, Lyons RJ, Haynes AM, Horvath LG, Kench JG, Stricker PD, Hayes VM.

Prostate. 2018 Jan;78(1):25-31. doi: 10.1002/pros.23440. Epub 2017 Nov 14.

PMID:
29134670
13.

Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer.

Valdés-Mora F, Gould CM, Colino-Sanguino Y, Qu W, Song JZ, Taylor KM, Buske FA, Statham AL, Nair SS, Armstrong NJ, Kench JG, Lee KML, Horvath LG, Qiu M, Ilinykh A, Yeo-Teh NS, Gallego-Ortega D, Stirzaker C, Clark SJ.

Nat Commun. 2017 Nov 7;8(1):1346. doi: 10.1038/s41467-017-01393-8.

14.

The evolution of chemotherapy for the treatment of prostate cancer.

Quinn DI, Sandler HM, Horvath LG, Goldkorn A, Eastham JA.

Ann Oncol. 2017 Nov 1;28(11):2658-2669. doi: 10.1093/annonc/mdx348. Review.

PMID:
29045523
15.

A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer.

Lin HM, Mahon KL, Weir JM, Mundra PA, Spielman C, Briscoe K, Gurney H, Mallesara G, Marx G, Stockler MR, PRIMe Consortium, Parton RG, Hoy AJ, Daly RJ, Meikle PJ, Horvath LG.

Int J Cancer. 2017 Nov 15;141(10):2112-2120. doi: 10.1002/ijc.30903. Epub 2017 Aug 8.

16.

A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer.

Zhang AY, Grogan JS, Mahon KL, Rasiah K, Sved P, Eisinger DR, Boulas J, Vasilaris A, Henshall SM, Stricker PD, Kench JG, Horvath LG.

Ann Oncol. 2017 Aug 1;28(8):1903-1909. doi: 10.1093/annonc/mdx247.

PMID:
28486686
17.

Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long-term follow-up.

Grogan J, Gupta R, Mahon KL, Stricker PD, Haynes AM, Delprado W, Turner J, Horvath LG, Kench JG.

BJU Int. 2017 Nov;120(5):651-658. doi: 10.1111/bju.13857. Epub 2017 Apr 30.

18.

Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer.

Lin HM, Mahon KL, Spielman C, Gurney H, Mallesara G, Stockler MR, Bastick P, Briscoe K, Marx G, Swarbrick A, Horvath LG.

Br J Cancer. 2017 Apr 11;116(8):1002-1011. doi: 10.1038/bjc.2017.50. Epub 2017 Mar 9.

19.

Loss of AZGP1 as a Superior Predictor of Relapse in Margin-Positive Localized Prostate Cancer.

Bruce HM, Stricker PD, Gupta R, Savdie RR, Haynes AM, Mahon KL, Lin HM, Kench JG, Horvath LG.

Prostate. 2016 Dec;76(16):1491-1500. doi: 10.1002/pros.23233. Epub 2016 Jul 30.

PMID:
27473574
20.

Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer.

Kalsbeek AM, Chan EF, Grogan J, Petersen DC, Jaratlerdsiri W, Gupta R, Lyons RJ, Haynes AM, Horvath LG, Kench JG, Stricker PD, Hayes VM.

Aging (Albany NY). 2016 Oct 5;8(11):2702-2712. doi: 10.18632/aging.101044.

Supplemental Content

Loading ...
Support Center